Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Files

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source a prespecified s.pdf (747.47 KB)

Date

2018

Type:

Article

Collections

Artículos Medicina y Ciencias de la Salud

Descargas totales

13

Vistas totales

1
Gestores bibliográficos

Authors

item.contributor.advisor

ORCID:

Journal Title

Journal ISSN

Volume Title

Publisher

item.page.isbn

item.page.issn

item.page.issne

item.page.doiurl

URI

https://doi.org/10.1016/S1474-4422(18)30319-3
 http://hdl.handle.net/11447/6098

item.page.extent

item.page.accessRights

item.page.other

item.page.references

Abstract

Background: Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent str...

Description

item.page.coverage.spatial

item.page.sponsorship

Citation

Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, Ameriso SF, Endres M, Lutsep H, Messé SR, Spence JD, Nedeltechev K, Perera K, Santo G, Olavarria V, Lindgren A, Bangdiwala S, Shoamanesh A, Berkowitz SD, Mundl H, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol. 2018 Dec;17(12):1053-1060. doi: 10.1016/S1474-4422(18)30319-3.

Keywords

Factor Xa Inhibitors / therapeutic use , Aspirin / therapeutic use , Cohort Studies , Female , International Cooperation , Platelet Aggregation Inhibitors / therapeutic use , Rivaroxaban / therapeutic use , Statistics, Nonparametric , Stroke / drug therapy

item.page.dc.rights

item.page.dc.rights.url

Estadísticas de uso
1 0,8 0,5 0,3 0
Agosto 2025Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026

Implementado por OpenGeek Services